From: Effects of vitamin D supplementation in endometriosis: a systematic review
Study | Country | Treatment | Vit D (n) | Vit D endometriosis rASRM stage | Vit D age | Vit D group Vit D levels (ng/ml) | Placebo (n) | Placebo endometriosis rASRM stage | Placebo age | Placebo Vit D levels (ng/ml) | Conclusions |
---|---|---|---|---|---|---|---|---|---|---|---|
Almassinokiani et al., 2016 [29] | Iran | 50 000 IU weekly for 12 weeks orally | 19 | I-II 11 III-IV 8 | 30.84 (5.79) | n/a | 19 (20) | I-II 9 III-IV 10 | 28.95 (4.71) | n/a | After ablative surgery for endometriosis, vitamin D treatment did not have a significant effect in reducing dysmenorrhea (p = 0.45) and/or pelvic pain (p = 0.24) |
Nodler et al., 2020 [30] | USA | 2000 IU daily for 24 weeks orally | 23 (27) | I-II 26 III-IV 1 | 20 (2.7) | Baseline 33.8 (4.5) 27 patients 6 months 42.5(4.8) 23 patients | 19 (22) | I-II 21 III-IV 1 | 20.1 (3.5) | Baseline 31.2 (5.0) 22 patients 6 months 33.5(5.3) 19 patients | In young women with endometriosis, supplementation with vitamin D led to significant changes in pelvic pain (p = 0.02); however, these were similar in magnitude to placebo |
Mehdizadehkashi et al., 2021 [31] | Iran | 50 000 IU every two weeks for 12 weeks orally | 25 (30) | n/a | 34 (7.1) | Baseline 24.7 (7.6) 3 months 36.8 (8.1) | 25 (30) | n/a | 35.6 (7.0) | Baseline 25.4 (10.0) 3 months 25.9 (10.7) | Vitamin D intake in patients with endometriosis resulted in a significant improvement of pelvic pain, total-/HDL-cholesterol ratio, hs-CRP and TAC levels, but did not affect other clinical symptoms and metabolic profiles |
Somigliana et al., 2021 [32] | Italy | single dose of 600,000 IU of vitamin D3 | 38 | n/a | 34.5 (2.5) | Baseline 21.8 (16.1–25.1) | 45 | n/a | 34 (3) | 19.7 (13.9–23.4) | In women with endometriosis, normal weight with preserved ovarian reserve and low vitamin D levels undergoing in vitro fertilization cycles, a single oral dose of 600,000 IU of vitamin D 3 did not improve the rate of clinical pregnancy |